PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

Area of Science:

• Immunology
• Molecular Biology
• Cancer Biology

Background:

• Programmed death-ligand 1 (PDL1) blockade is a key cancer immunotherapy, primarily understood to enhance anti-tumor T cell responses by inhibiting PDL1-PD1 interactions.
• The precise mechanisms by which PDL1 influences cancer cells directly remain incompletely understood.

Purpose of the Study:

• To investigate the cell-intrinsic functions of PDL1 in cancer cells beyond its role in T cell regulation.
• To elucidate the molecular mechanisms by which PDL1 affects cancer cell sensitivity to interferon (IFN) and impacts tumor progression.

Main Methods:

• Analysis of PDL1 sequence motifs involved in IFN signaling crosstalk.
• Experimental manipulation of PDL1 expression and antibody blockade in cancer cells.
• Investigation of downstream signaling pathways including STAT3 and caspase-7.
• Examination of somatic mutations in PDL1 motifs from human carcinomas.

Main Results:

• PDL1 directly inhibits interferon (IFN) signal transduction through conserved sequence motifs.
• Abrogation or blockade of PDL1 sensitizes cancer cells to IFN-induced cytotoxicity via a STAT3/caspase-7 pathway.
• Somatic mutations in PDL1 motifs enhance its protective activity against type I and type II IFN cytotoxicity.
• PDL1 functions as an intrinsic shield for cancer cells against IFN-mediated cell death, promoting tumor progression.

Conclusions:

• PDL1 possesses a critical cell-intrinsic role in protecting cancer cells from IFN cytotoxicity, independent of T cell interactions.
• This PDL1-mediated protection mechanism involves direct inhibition of IFN signaling pathways.
• Mutations within PDL1 motifs can augment its cancer-protective functions, highlighting a novel therapeutic vulnerability.